Skip to main content

Ozempic (semaglutide) shortage collection

There is a worldwide shortage of this diabetes medicine. TGA alerts relate to the shortage in Australia.

Increased global demand for semaglutide products is impacting availability of Ozempic (semaglutide) in Australia. Alerts on the shortage of Trulicity (dulaglutide) and Mounjaro (tirzepatide) are also accessible from this collection.

Read current information and updates at:
About the Ozempic (semaglutide) shortage 2022 and 2023
About the Trulicity (dulaglutide) shortage 2022 and 2023

The pharmaceutical company that supplies Ozempic, Novo Nordisk, has recently advised the TGA and the Ozempic Medicine Shortage Action Group that supply throughout the rest of the year and into 2024 will be limited. Currently we are asking health professionals not to prescribe Ozempic to new patients to conserve supply for patients who are already stabilised on this medicine and who do not have suitable alternatives.

Visit the Medicine shortage reports database to search for all medicines in shortage and find information about management actions.

Collection content

10 result(s) found, displaying 1 to 10

Help us improve the Therapeutic Goods Administration site